<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04586881</url>
  </required_header>
  <id_info>
    <org_study_id>HDZ_ER001_CS</org_study_id>
    <nct_id>NCT04586881</nct_id>
  </id_info>
  <brief_title>Catch me if You Can - the Individual Relationship Between Potential Ablation Targets From CARTOFINDER and Myocardial Fibrosis</brief_title>
  <official_title>Catch me if You Can - the Individual Relationship Between Potential Ablation Targets From CARTOFINDER and Myocardial Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heart and Diabetes Center North-Rhine Westfalia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biosense Webster, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Heart and Diabetes Center North-Rhine Westfalia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single center observational study to compare the relationship between atrial fibrosis and&#xD;
      potential ablation targets from CARTOFINDER.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total number of 30 patients will undergo catheter Ablation for persistent AF.&#xD;
      Pre-procedural cardiac MRI will be performed with late-gadolinium enhancement to visualize&#xD;
      the individual amount and distribution of fibrosis in the right and left atrium.&#xD;
      CARTOFINDER-guided mapping will be performed during the ablation procedure followed by AF&#xD;
      ablation. The individual relationship between atrial fibrosis and potential ablation targets&#xD;
      will be accessed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Anticipated">March 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>AF recurrence</measure>
    <time_frame>12 months</time_frame>
    <description>recurrence of atrial fibrillation after catheter ablation</description>
  </primary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Atrial Fibrillation</condition>
  <eligibility>
    <study_pop>
      <textblock>
        A total of 20 consecutive patients with drug-refractory persistent AF will be included in&#xD;
        this prospective observational analysis. AF will be defined as persistent if episodes&#xD;
        lasted &gt; 7 days or required electrical or pharmacological cardioversion after ≥ 48 h from&#xD;
        onset. All patients will be treated for AF at the Heart and Diabetes Center NRW, Bad&#xD;
        Oeynhausen, Germany. Written informed will be obtained from each patient, the study concept&#xD;
        complies with the Declaration of Helsinki and the institutional review board already&#xD;
        approved the study design. Catheter ablation will be performed under deep sedation. In all&#xD;
        patients preprocedural Magnetic Resonance Imaging (MRI) will be performed to guide the&#xD;
        intervention, visualize the individual amount and distribution of fibrosis and to visualize&#xD;
        the anatomical location and course of the esophagus.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients undergoing their 1st AF ablation procedure for persistent atrial fibrillation&#xD;
             (AF) as per recent Heart Rhythm Society (HRS) consensus document&#xD;
&#xD;
          2. Able to understand and willing to sign the Informed Consent Form.&#xD;
&#xD;
          3. Age ≥18 years.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Contraindication for DE-MRI with a full dose of Gadolinium-based contrast agent.&#xD;
&#xD;
          2. Previous left atrial ablation or surgical procedure&#xD;
&#xD;
          3. Renal failure with CrCl &lt;60 ml/min&#xD;
&#xD;
          4. Women currently pregnant, breastfeeding, or of childbearing age not currently taking&#xD;
             or not willing to use a reliable form of contraception&#xD;
&#xD;
          5. Mental or physical inability to take part in the study&#xD;
&#xD;
          6. Uncontrolled hypertension&#xD;
&#xD;
          7. Morbid obesity (BMI &gt; 35), or inability to be placed in MRI due to body mass.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Christian Sohns, MD</last_name>
    <phone>49 5731 971327</phone>
    <email>csohns@hdz-nrw.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Astrid KIeemeyer</last_name>
    <phone>49 5731 971258</phone>
    <email>akleemeyer@hdz-nrw.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Herz- und Diabeteszentrum NRW, Ruhr-Universität Bochum</name>
      <address>
        <city>Bad Oeynhausen</city>
        <zip>32545</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Astrid R Kleemeyer</last_name>
      <phone>+49495731971258</phone>
      <email>akleemeyer@hdz-nrw.de</email>
    </contact>
    <investigator>
      <last_name>Christian Sohns, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 7, 2020</study_first_submitted>
  <study_first_submitted_qc>October 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2020</study_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

